METHODS: The studied group comprises 124 patients with acute myocardial infarction on dual antiplatelet therapy with acetylsalicylic acid (ASA) and thienopyridines. Antiplatelet therapy was monitored by platelet-rich plasma light transmittance aggregometry (LTA) using the APACT 4004 analyzer (Helena Laboratories) and by whole blood impedance aggregometry (multiple electrode aggregometry [MEA]) using the Multiplate analyzer (Dynabyte). Platelet aggregation was detected after stimulation with arachidonic acid for detection of aspirin resistance and with adenosine diphosphate (ADP) and prostaglandin E1 for detection of thienopyridine resistance. To determine the frequencies of P2Y12 (i-744T>C; rs2046934), P2Y12 (34C>T; rs6785930), COX-1 (-842A>G; rs10306114), GPVI (13254T>C; rs1613662), and GPIbA (5T>C; rs2243093) polymorphisms, DNA of patients with AIM was tested by real-time-polymerase chain reaction and melting curve analysis using the LightCycler 480 analyzer (Roche Diagnostics). RESULTS: The cut-off points used for patients with effective ASA therapy are 25% of aggregated platelets and 220 area under the curve (AUC)/min if LTA or MEA, respectively. The cut-off points used for effective thienopyridine therapy are 45% of aggregated platelets or 298 AUC/min, respectively. Both LTA and MEA found that aspirin and thienopyridine therapies failed in 14.51% and 25.8%, respectively. The data were statistically processed using the SPSS version 15 software (SPSS, Inc.). Associations between receptor mutation status and response to therapy were assessed with Fisher's exact test. The significance level was set at 0.05. CONCLUSION: The aim of our work was to use the two functional laboratory methods described earlier to assess both aspirin and thienopyridine resistance and to determine the contribution of genetic polymorphisms of platelet receptors to resistance to antiplatelet therapy in AIM. Fisher's exact test showed a significant statistical correlation between platelet function tests suitable for monitoring ASA resistance, that is, LTA and MEA, and mutation status of COX1_A1 (-A842G). Fisher's exact test showed no statistically significant correlations between platelet function tests suitable for monitoring ASA resistance, that is, LTA and MEA, and mutation status of GP1bA (-5T>C) and GP6 (T13254C). Fisher's exact test showed no statistically significant correlation between mutational statuses of the receptors P2RY12 (i-T744C), P2RY12 (C34T), GP1bA (-5T>C), or GP6 (T13254C) and response to antiplatelet therapy with 75 mg of clopidogrel.

Department of Hemato Oncology Faculty of Medicine and Dentistry Palacky University Olomouc and University Hospital Olomouc Czech Republic

Zobrazit více v PubMed

Abaci O, Kilickesmez KO. (2013) Aspirin resistance: where are we now? Anadolu Kardiol Derg 13:370–373 PubMed

Antoniades C, Tousoulis D, Vasiliadou C, et al. (2006) Genetic polymorphisms of platelet glycoprotein Ia and the risk for premature myocardial infarction: effects on the release of sCD40L during the acute phase of premature myocardial infarction. J Am Coll Cardiol 47:1959–1966 PubMed

Blais N, Pharad C, Lordkipanidze M, et al. (2009) Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B2. Thromb Haemost 102:404–411 PubMed

Cattaneo M, Lecchi A, Zighetti ML, et al. (2007) Platelet aggregation studies: autologous platelet poor plasma inhibits platelet aggregation when added to platelet rich plasma to normalize platelet count. Haematologica 92:694–697 PubMed

Cattaneo M. (2007) Resistance to platelet drugs: molecular mechanisms and laboratory detection. J Thromb Haemost 5:230–237 PubMed

Cuisset T, Frere C, Quilici J, et al. (2009) Aspirin noncompliance is the major cause of “aspirin resistance” in patients undergoing coronary stenting. Am Heart J 157:889–893 PubMed

Gurbel PA, Tandry US. (2007) Clopidogrel resistance? Thromb Res 120:311–321 PubMed

Kvasnička J, Hajkova J, Bobčikova P, et al. (2008) Polymorfizmy krevních destiček a možnosti monitorace účinku protidestičkové léčby. Interv Akut Kardiol 7:215–218

Lepäntalo A, Mikkelsson J, Reséndiz JC, et al. (2006) Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients. Thromb Haemost 95:253–259 PubMed

Linnemann B, Schwonberg J, Mani H, et al. (2008) Standardization of light transmittance aggregometry for monitoring antiplatelet therapy: an adjustment for platelet count is not necessary. J Thromb Haemost 6:677–683 PubMed

Mueller T, Dieplinger B, Poelz W, et al. (2007) Utility of whole blood impedance aggregometry for the assessment of clopidogrel action using the novel Multiplate analyzer—comparison with two flow cytometric methods. Thromb Res 121:249–258 PubMed

Rudež G, Pons D, Leebeek F, et al. (2008) Platelet receptor P2RY12 haplotypes predict restenosis after percutaneous coronary interventions. Hum Mutat 29:375–380 PubMed

Ševčíková H. (2006) Rezistence na protidestičkovou terapii. Interv Akut Kardiol 5:256–258

Seyfert UT, Haubelt H, Vogt A, et al. (2007) Variables influencing Multiplate(TM) whole blood impedance platelet aggregometry and turbidimetric platelet aggregation in healthy individuals. Platelets 18:199–206 PubMed

Slavik L, Úlehlová J, Krcova V, et al. (2011) Detection of clopidogrel resistance by MEA and LTA. Transfuze a Hematologie Dnes 17:92–96

Úlehlová J, Slavík L, Krčová V, et al. (2011) The assessment of aspirin resistance by using light transmission and multiple electrode aggregometry. Int J Lab Hematol 33:305–309 PubMed

Association of polymorphisms of platelet receptors GPIa (807C>T), GPVI (13254T>C), and P2Y12 (34C>T and H1/H2 haplotype) with increased risk of periprocedural bleeding in patients undergoing coronary angiography/percutaneous coronary intervention